Oral Nutritional Supplementation of Hemodialysis Patients - Trial NCT05333692
Access comprehensive clinical trial information for NCT05333692 through Pure Global AI's free database. This phase not specified trial is sponsored by Fresenius Kabi Taiwan Ltd. and is currently Completed. The study focuses on Hemodialysis Complication. Target enrollment is 90 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Fresenius Kabi Taiwan Ltd.
Timeline & Enrollment
N/A
Jul 01, 2020
May 06, 2021
Primary Outcome
Serum Albumin level change
Summary
This study is aimed to demonstrate that increase in serum albumin concentration (week 8
 -baseline) after test treatment (Fresubin® Protein Energy DRINK), a standard ONS, is not
 relevantly smaller than that after control treatment with NEPRO®.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05333692
Non-Device Trial